| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GUCY2C |
| Uniprot No | P25092 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-430aa |
| 氨基酸序列 | SQVSQNCHNGSYEISVLMMGNSAFAEPLKNLEDAVNEGLEIVRGRLQNAGLNVTVNATFMYSDGLIHNSGDCRSSTCEGLDLLRKISNAQRMGCVLIGPSCTYSTFQMYLDTELSYPMISAGSFGLSCDYKETLTRLMSPARKLMYFLVNFWKTNDLPFKTYSWSTSYVYKNGTETEDCFWYLNALEASVSYFSHELGFKVVLRQDKEFQDILMDHNRKSNVIIMCGGPEFLYKLKGDRAVAEDIVIILVDLFNDQYFEDNVTAPDYMKNVLVLTLSPGNSLLNSSFSRNLSPTKRDFALAYLNGILLFGHMLKIFLENGENITTPKFAHAFRNLTFEGYDGPVTLDDWGDVDSTMVLLYTSVDTKKYKVLLTYDTHVNKTYPVDMSPTFTWKNSKLPNDITGRGPQ |
| 预测分子量 | 74.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GUCY2C重组蛋白的3篇参考文献示例(内容基于公开研究概括，非真实文献)：
1. **文献名称**：*Targeting GUCY2C with a recombinant viral vector vaccine induces antigen-specific antitumor immunity in colorectal cancer models*
**作者**：Snook AE, et al.
**摘要**：该研究开发了一种基于重组腺病毒载体的GUCY2C靶向疫苗，在结直肠癌小鼠模型中成功诱导了抗原特异性CD8+ T细胞反应，抑制肿瘤生长并延长生存期，验证了GUCY2C作为免疫治疗靶点的潜力。
2. **文献名称**：*Structural insights into ligand binding and activation of GUCY2C through cryo-EM analysis*
**作者**：Kim YS, et al.
**摘要**：通过冷冻电镜解析GUCY2C重组蛋白与天然配体鸟苷肽(guanylin)结合的三维结构，揭示了其胞外域构象变化及跨膜信号传导机制，为设计靶向药物提供结构基础。
3. **文献名称**：*Recombinant GUCY2C extracellular domain inhibits bacterial heat-stable enterotoxin-induced diarrhea*
**作者**：London RM, et al.
**摘要**：研究显示，表达并纯化的GUCY2C胞外重组蛋白可竞争性结合致病性大肠杆菌热稳定肠毒素(STa)，阻断其与肠道细胞受体的相互作用，在动物模型中有效缓解毒素引起的腹泻症状。
4. **文献名称**：*GUCY2C-directed CAR-T cells utilizing a recombinant scFv antibody fragment show potent cytotoxicity against gastrointestinal cancers*
**作者**：Alcala TE, et al.
**摘要**：构建基于重组GUCY2C单链抗体(scFv)的CAR-T细胞，在体外和体内实验中特异性杀伤GUCY2C高表达的胃癌和结直肠癌细胞，为实体瘤免疫治疗提供新策略。
(注：以上文献为示例性概括，实际引用请核实真实出版物。)
GUCY2C, a receptor guanylyl cyclase predominantly expressed in intestinal epithelial cells, plays a critical role in maintaining electrolyte and fluid homeostasis by converting GTP to cyclic GMP (cGMP) upon activation by its ligands, guanylin and uroguanylin. Structurally, it consists of an extracellular ligand-binding domain, a transmembrane region, and a cytoplasmic catalytic domain. Beyond its physiological functions, GUCY2C has gained attention as a tumor-associated antigen due to its selective overexpression in >95% of colorectal cancers (CRCs) while remaining restricted to normal intestinal tissues. This unique expression profile positions it as a promising target for diagnostic and therapeutic strategies against CRC and metastatic lesions.
Recombinant GUCY2C protein, produced through heterologous expression systems (e.g., E. coli or mammalian cells), retains antigenic epitopes critical for immunological applications. Researchers employ it as both an immunogen for vaccine development and a detection reagent in diagnostic assays. Recent studies highlight its utility in generating monoclonal antibodies and chimeric antigen receptor (CAR) T-cell therapies designed to recognize GUCY2C-positive cancer cells. However, challenges persist in maintaining proper post-translational modifications (e.g., glycosylation) during recombinant production, which may affect receptor-ligand interactions and immunogenicity. Current efforts focus on optimizing expression platforms and purification methods to preserve structural integrity while ensuring scalability for clinical translation. As CRC remains a leading cause of cancer mortality globally, GUCY2C-targeted biologics derived from recombinant proteins continue to offer novel avenues for precision oncology.
×
